Regorafenib has become a standard later stage treatment of metastatic colorectal carcinoma (mCRC) worldwide, though particular side effects such as fatigue and diarrhoea complicate its use in practice. Until now, consensus was split on how to use regorafenib for effective treatment - should the full dose be initiated and reduced until tolerated, or should a lower initial dose be used with a view to titrate up?

The REDOS trial evaluated the safety and activity of two regorafenib dosing schedules in patients with refractory mCRC. An escalation strategy was implemented to optimise the dose of regorafenib and to improve the tolerability of this drug to patients while maintaining survival benefits.

Join lead investigator Dr Tanois Bekaii-Saab and Dr Axel Grothey for a critical analysis of the trial, and a discussion of future directions in this therapy area.

If you are from Spain, Italy, France or the USA and want to listen to advice from experts from your country, please visit Oncology knowledge into practice.

This independent educational activity is supported by an educational grant from Bayer Pharmaceuticals. All educational content has been developed by Liberum IME and validated by an independent steering committee; Bayer Pharmaceuticals have had no influence on the content of this education.